GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » LumiraDx Ltd (OTCPK:LMDWF) » Definitions » Total Stockholders Equity

LumiraDx (LumiraDx) Total Stockholders Equity : $-213.83 Mil (As of Jun. 2023)


View and export this data going back to 2021. Start your Free Trial

What is LumiraDx Total Stockholders Equity?

LumiraDx's Total Stockholders Equity for the quarter that ended in Jun. 2023 was $-213.83 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. LumiraDx's Book Value per Share for the quarter that ended in Jun. 2023 was $N/A. The ratio of a company's debt over equity can be used to measure how leveraged this company is. LumiraDx's Debt-to-Equity for the quarter that ended in Jun. 2023 was -1.88.


LumiraDx Total Stockholders Equity Historical Data

The historical data trend for LumiraDx's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LumiraDx Total Stockholders Equity Chart

LumiraDx Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Total Stockholders Equity
- -375.01 163.05 -105.11

LumiraDx Quarterly Data
Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.81 18.08 -105.11 -153.43 -213.83

LumiraDx  (OTCPK:LMDWF) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

LumiraDx's Book Value per Share for the quarter that ended in Jun. 2023 is

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

LumiraDx's Debt-to-Equity for the quarter that ended in Jun. 2023 is

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


LumiraDx Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of LumiraDx's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


LumiraDx (LumiraDx) Business Description

Traded in Other Exchanges
Address
C/o Ocorian Trust (Cayman) Ltd, Windward 3, P.O. Box 1350, Regatta Office Park, Grand Cayman, CYM, KY1-1108
LumiraDx Ltd is a next-generation point of care diagnostics company. It manufactures and commercializes an innovative diagnostic Platform that supports a broad menu of tests with lab comparable performance at the point of care. Geographical presence in United States, Italy, UK, Germany, Colombia, Sweden and Other countries. Majority revenue derives from U.S.